Skip to main content
. 2023 May 18;13(5):e067343. doi: 10.1136/bmjopen-2022-067343

Table 5.

Documented process outcomes by intervention period

Pre-intervention Post-intervention 1 Post-intervention 2
n of total
(%)
n of total (%) OR* (95% CI) compared with pre-intervention n of total (%) OR* (95% CI) compared with pre-intervention OR† (95% CI) compared with post-intervention 1
Glucose test documented, among those with a neurologic chief complaint 145 of 560 (25.9) 254 of 672 (37.1) 1.74 (1.36 to 2.22) 169 of 469 (35.2) 1.61 (1.23 to 2.11) 0.93 (0.73 to 1.18)
Antibiotics documented, among those with a final diagnosis of presumed bacterial infection 154 of 441 (34.8) 415 of 478 (86.5) 12.28 (8.83 to 17.07) 335 of 388 (85.7) 11.78 (8.30 to 16.71) 0.96 (0.65 to 1.42)
Malaria test recorded, among those with a documented fever 139 of 229 (60.7) 168 of 221 (76.0) 2.05 (1.37 to 3.08) 179 of 242 (74.0) 1.84 (1.24 to 2.72) 0.91 (0.59 to 1.38)
Oxygen delivery recorded, among those with documented hypoxia 3 of 27 (11.1) 20 of 71 (28.2) 3.14 (0.85 to 11.59) 15 of 42 (35.7) 4.44 (1.15 to 17.25) 1.42 (0.63 to 3.20)
Repeat set of vital signs recorded, among those with initial shock vital signs‡ 4 of 61 (6.6) 49 of 193 (25.4) 8.85 (1.67 to 14.06) 34 of 135 (25.2) 4.80 (1.62 to 14.21) 0.99 (0.60 to 1.64)
IVF documented, among those with initial shock vital signs‡ 16 of 45 (35.6) 41 of 192 (21.4) 0.76 (0.39 to 1.49) 23 of 135 (17.0) 0.58 (0.28 to 1.19) 0.76 (0.43 to 1.33)

*ORs calculated with pre-intervention group as baseline odds.

†ORs calculated for post-intervention 2 group with post-intervention 1 group as baseline odds.

‡Shock identified by appropriate vital signs according to age.

IVF, intravenous fluids.